These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21810381)

  • 1. Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism.
    Pepene CE; Crişan N; Coman I
    Clin Invest Med; 2011 Aug; 34(4):E232. PubMed ID: 21810381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
    Baek KH; Oh KW; Lee WY; Tae HJ; Rhee EJ; Han JH; Cha BY; Kim YJ; Lee KW; Son HY; Kang SK; Kim CC; Kang MI
    Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.
    Pepene CE; Ilie IR; Marian I; Duncea I
    Eur J Endocrinol; 2011 Jan; 164(1):61-8. PubMed ID: 20974706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
    Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
    Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.
    Kulcsar-Jakab E; Petho Z; Pap Z; Kalina E; Foldesi R; Balogh A; Antal-Szalmas P; Bhattoa HP
    BMC Musculoskelet Disord; 2015 Aug; 16():227. PubMed ID: 26311162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis.
    Dovio A; Data V; Carignola R; Calzolari G; Vitetta R; Ventura M; Saba L; Severino A; Angeli A
    J Rheumatol; 2008 Nov; 35(11):2206-13. PubMed ID: 18843778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
    J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure.
    Fahrleitner-Pammer A; Dobnig H; Dimai HP; Holzer H; Benesch T; Borchhardt K; Cejka D; Haas M
    Clin Nephrol; 2009 Jun; 71(6):652-9. PubMed ID: 19473634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
    Kananen K; Volin L; Laitinen K; Ruutu T; Välimäki MJ
    Osteoporos Int; 2006; 17(5):724-30. PubMed ID: 16437190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population.
    Trofimov S; Pantsulaia I; Kobyliansky E; Livshits G
    Eur J Endocrinol; 2004 Mar; 150(3):305-11. PubMed ID: 15012615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the relationship between melatonin, hormones of the pituitary-ovarian, -thyroid and -adrenocortical axes, and osteoprotegerin and its ligand sRANKL in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Wołkowska-Pokrywa K; Szapska B
    Postepy Hig Med Dosw (Online); 2013 May; 67():433-41. PubMed ID: 23752595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
    Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
    Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin, Receptor Activator of Nuclear Factor Kappa B Ligand, and Growth Hormone/Insulin-Like Growth Factor-1 Axis in Children with Growth Hormone Deficiency.
    Witkowska-Sędek E; Rumińska M; Stelmaszczyk-Emmel A; Sobol M; Demkow U; Pyrżak B
    Adv Exp Med Biol; 2018; 1116():63-73. PubMed ID: 30284692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin and receptor activator of the nuclear factor kappa B ligand (RANKL) in healthy pubertal girls - relationships with physical growth and classical bone turnover markers.
    Kulik-Rechberger B; Kozłowska M
    J Physiol Pharmacol; 2024 Feb; 75(1):. PubMed ID: 38583439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
    Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.